I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Salubris (002294.SZ) announced that the innovative gene-editing drug YOLT-101 injection introduced by the company has received the clinical trial implicit approval from the National Medical Products Administration. The indication for this drug is heterozygous familial hypercholesterolemia (HeFH)